A number of years ago while I was still in the pharmaceutical industry, Sandoz spoke of an extensive pipeline of a new generation of drugs in the biological area known as bio-similars. A couple of these products have come to market in the past few years.
Think of these products as generic versions of biologicals. They represent a significant potential savings for health plans. Litigation and laws for interchange by the states have restricted these products reaching the patients.
This article shows where the states are in regard to making bio-similars interchangeable with their brand biological products:
